Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Finland. It develops immunotherapies designed to influence the tumour microenvironment, with its main candidate being bexmarilimab, an antibody aimed at reprogramming myeloid cells to support the body's immune response against cancer. The company also has earlier research experience in treatments for severe inflammatory conditions affecting the lungs. Its work is aimed at cancer care and hospital-based treatment settings, and it operates as a research and development business rather than a commercial manufacturer.
The shares are listed on the London Exchange in UK under the code FARN, and the price on this page is in pence sterling (GBX). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Weak price profile
Ranks #3591 of 3787 on the London Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for UK yet.
TrendWeak
3/100
Below its long-term averages and far from its highs.
See the numbers →
Above 200-day average-42.1%
From 52-week high-84.1%
MomentumWeak
10/100
Lagging most stocks on this exchange.
See the numbers →
3-month return-20.7%
6-month return-25.1%
12-month, skipping last month-79.7%
Stability (higher is calmer)Weak
5/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)105.6%
Worst drawdown, 1 year (smaller is calmer)-84.1%
LiquidityFair
60/100
Moderate trading activity.
See the numbers →
Avg daily value traded2.04M GBX
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for UK when fundamentals data for this market is added. All UK stocks.
52-wk range 32.00 – 210.00Daily closes, split-adjusted
Signals
50-day average36.80
200-day average56.13
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)2.69
Technical summary
Daily
Bearish
4 bullish · 0 neutral · 12 bearish
Weekly
Strongly bearish
1 bullish · 0 neutral · 11 bearish
Monthly
Strongly bearish
0 bullish · 1 neutral · 7 bearish
Moving averages (daily)
SMA 10
35.25
Bearish
EMA 10
34.81
Bearish
SMA 20
36.08
Bearish
EMA 20
35.49
Bearish
SMA 50
36.80
Bearish
EMA 50
37.00
Bearish
SMA 100
39.43
Bearish
EMA 100
42.69
Bearish
SMA 200
56.13
Bearish
EMA 200
64.98
Bearish
Oscillators (daily)
RSI (14)
23.05
Bullish
MACD (12, 26)
-0.78
Bearish
Momentum (12)
-10.96
Bearish
Stochastic %K (14)
8.33
Bullish
Williams %R (14)
-91.67
Bullish
CCI (20)
-234.4
Bullish
Pivot points (classic, last session)
S3
31.00
S2
31.50
S1
32.00
Pivot
32.50
R1
33.00
R2
33.50
R3
34.00
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in GBX. Educational only, not financial advice.
